Correction of SCID-X1 using an enhancerless vav promoter

Human Gene Therapy

Volumn 22, Issue 3, 2011, Pages 263-270

  Almarza, E ^a,b   Zhang, F ^b   Santilli, G ^b   Blundell, M P ^b   Howe, S J ^b   Thornhill, S I ^b   Bueren, J A ^a   Thrasher, A J ^b,c  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; STAT5 PROTEIN; VAV PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL LINE; CONTROLLED STUDY; COPY NUMBER VARIATION; EX VIVO GENE TRANSFER; GENE EXPRESSION; GRAFT RECIPIENT; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENE ORDER; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-2; LENTIVIRUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-VAV; SIGNAL TRANSDUCTION; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

MURINAE;

EID: 79952670909     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.119     Document Type: Article

References (39)

1. Almarza, E., Rio, P., Meza, N.W., et al. (2007). Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy. Mol. Ther. 15, 1487-1494. (Pubitemid 47099306)
2. Amorosi, S., Russo, I., Amodio, G., et al. (2009). The cellular amount of the common gamma-chain influences spontaneous or induced cell proliferation. J. Immunol. 182, 3304-3309.
3. Asao, H., Okuyama, C., Kumaki, S., et al. (2001). Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167, 1-5. (Pubitemid 32567752)
4. Baum, C., Von Kalle, C., Staal, F.J., et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther. 9, 5-13. (Pubitemid 38208322)
5. Baum, C., Kustikova, O., Modlich, U., et al. (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther. 17, 253-263.
6. Brooks, A.R., Harkins, R.N., Wang, P., et al. (2004). Transcrip-tional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J. Gene Med. 6, 395-404. (Pubitemid 40228056)
7. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672. (Pubitemid 30241569)
8. Custer, R.P., Bosma, G.C., and Bosma, M.J. (1985). Severe combined immunodeficiency (SCID) in the mouse. Pathology, re-constitution, neoplasms. Am. J. Pathol. 120, 464-477. (Pubitemid 15250108)
9. Dave, U.P., Akagi, K., Tripathi, R., et al. (2009). Murine leuke-mias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet. 5, e1000491.
10. DiSanto, J.P., Muller, W., Guy-Grand, D., et al. (1995). Lymphoid development in mice with a targeted deletion of the inter-leukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. U.S.A. 92, 377-381.
11. Gaspar, H.B., Parsley, K.L., Howe, S., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187. (Pubitemid 40018447)
12. Ginn, S.L., Liao, S.H., Dane, A.P., et al. (2010). Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gc overexpression. Mol. Ther. 18, 965-976.
13. Grassi, G., Maccaroni, P., Meyer, R., et al. (2003). Inhibitors of DNA methylation and histone deacetylation activate cyto-megalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 24, 1625-1635. (Pubitemid 37304667)
14. Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by exvivo gene therapy. N. Engl. J. Med. 346, 1185-1193. (Pubitemid 34984579)
15. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256. (Pubitemid 36077924)
16. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
17. Krishnan, M., Park, J.M., Cao, F., et al. (2006). Effects of epige-netic modulation on reporter gene expression: implications for stem cell imaging. FASEB J. 20, 106-108. (Pubitemid 43100482)
18. Kumaki, S., Ishii, N., Minegishi, M., et al. (1999). Functional role of interleukin-4 (IL-4) and IL-7 in the development of X-linked severe combined immunodeficiency. Blood 93, 607-612. (Pubitemid 29035742)
19. Kustikova, O., Fehse, B., Modlich, U., et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308, 1171-1174. (Pubitemid 40696434)
20. Lombardo, A., Genovese, P., Beausejour, C.M., et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298-1306. (Pubitemid 350076515)
21. Modlich, U., Navarro, S., Zychlinski, D., et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 17, 1919-1928.
22. Montini, E., Cesana, D., Schmidt, M., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-696. (Pubitemid 43882120)
23. Nienhuis, A.W., Dunbar, C.E., and Sorrentino, B.P. (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13, 1031-1049. (Pubitemid 43779188)
24. Noguchi, M., Adelstein, S., Cao, X., and Leonard, W.J. (1993a). Characterization of the human interleukin-2 receptor gamma chain gene. J. Biol. Chem. 268, 13601-13608. (Pubitemid 23307791)
25. Noguchi, M., Yi, H., Rosenblatt, H.M., et al. (1993b). Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147-157. (Pubitemid 23115456)
26. Ogilvy, S., Elefanty, A.G., Visvader, J., et al. (1998). Transcrip-tional regulation of vav, a gene expressed throughout the he-matopoietic compartment. Blood 91, 419-430. (Pubitemid 28053363)
27. Orlic, D., Girard, L.J., Lee, D., et al. (1997). Interleukin-7R alpha mRNA expression increases as stem cells differentiate into T and B lymphocyte progenitors. Exp. Hematol. 25, 217-222. (Pubitemid 27130298)
28. Otsu, M., Anderson, S.M., Bodine, D.M., et al. (2000). Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol. Ther. 1, 145-153.
29. Santilli, G., Thornhill, S.I., Kinnon, C., and Thrasher, A.J. (2008). Gene therapy of inherited immunodeficiencies. Expert Opin. Biol. Ther. 8, 397-407. (Pubitemid 351570406)
30. Schambach, A., Bohne, J., Baum, C., et al. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13, 641-645.
31. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B.P. (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 11730-11735. (Pubitemid 44182519)
32. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granuloma-tous disease. Nat. Med. 16, 198-204.
33. Takeshita, T., Asao, H., Ohtani, K., et al. (1992). Cloning of the gamma chain of the human IL-2 receptor. Science 257, 379-382.
34. Thornhill, S.I., Schambach, A., Howe, S.J., et al. (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther. 16, 590-598. (Pubitemid 351315000)
35. White, H., Thrasher, A., Veys, P., et al. (2000). Intrinsic defects of B cell function in X-linked severe combined immunodeficiency. Eur. J. Immunol. 30, 732-737. (Pubitemid 30216244)
36. Woods, N.B., Muessig, A., Schmidt, M., et al. (2003). Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of in-sertional mutagenesis. Blood 101, 1284-1289. (Pubitemid 36182497)
37. Woods, N.B., Bottero, V., Schmidt, M., et al. (2006). Gene therapy: therapeutic gene causing lymphoma. Nature 440, 1123.
38. Zhang, F., Thornhill, S.I., Howe, S.J., et al. (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chro-matin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 110, 1448-1457. (Pubitemid 47443959)
39. Zhou, S., Mody, D., Deravin, S.S., et al. (2010). A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 116, 900-908.